Canada’s role in the emerging cannabinoid revolution just took another step forward this week—further highlighting that the country will be at the forefront of development for the foreseeable future.
The makers of a new form of cannabinoid prodrugs called “cannabosides,” have officially announced they’re launching a Canadian subsidiary focused on cannabinoid genetics research and development.
Vitality Biopharma, Inc. (OTC: VBIO) announced the formation of a wholly-owned Canadian subsidiary, Vitality Genetics, Ltd., which will focus on and enable the performance of a wide variety of cannabinoid R&D programs.
The company’s current flagship property is its proprietary cannabosides prodrugs, which facilitate the unlocking of the full potential of cannabinoids for the treatment of serious neurological and inflammatory disorders—which among Vitality’s earliest profiles includes tackling gut disorders such as Crohn’s disease.
